Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy.
Albumin-bilirubin grade
Biliary tract cancers
CA19-9
Radiation therapy
Survival
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
28
02
2024
accepted:
27
06
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
1
8
2024
Statut:
epublish
Résumé
Biliary tract cancers (BTC) are rare and aggressive malignancies originating from intrahepatic and extrahepatic bile ducts and the gallbladder. Surgery is the only curative option, but due to late-stage diagnosis, is frequently not feasible, leaving chemotherapy as the primary treatment. Radiotherapy (RT) can be an effective alternative for patients with unresectable, non-metastatic BTC despite the generally poor prognosis and significant variability. To help manage patients with unresectable BTC who receive RT, we aimed to identify prognostic markers that could aid in predicting overall survival (OS). A retrospective cohort study was conducted at the University of Pennsylvania, involving seventy-eight patients with unresectable BTC treated with definitive intent RT. Comprehensive demographic, clinical, and treatment-related data were extracted from the electronic medical records. Univariate and multivariate Cox regressions were employed to identify predictors of OS after RT. A biomarker model was developed for refined survival prediction. The cohort primarily comprised patients with good performance status without significant hepatic dysfunction at presentation. The predominant treatment approach involved hypofractionated RT or concurrent 5FU-based chemoRT. Median OS after RT was 12.3 months, and 20 patients (15.6%) experienced local progression with a median time of 30.1 months. Univariate and multivariate analyses identified CA19-9 (above median) and higher albumin-bilirubin (ALBI) grades at presentation as significant predictors of poor OS. Median OS after RT was 24 months for patients with no risk factors and 6.3 months for those with both. Our study demonstrates generally poor but significantly heterogeneous OS in patients with unresectable BTC treated with RT. We have developed a biomarker model based on CA19-9 and ALBI grade at presentation that can distinguish sub-populations with markedly diverse prognoses. This model can aid the clinical management of this challenging disease.
Sections du résumé
BACKGROUND
BACKGROUND
Biliary tract cancers (BTC) are rare and aggressive malignancies originating from intrahepatic and extrahepatic bile ducts and the gallbladder. Surgery is the only curative option, but due to late-stage diagnosis, is frequently not feasible, leaving chemotherapy as the primary treatment. Radiotherapy (RT) can be an effective alternative for patients with unresectable, non-metastatic BTC despite the generally poor prognosis and significant variability. To help manage patients with unresectable BTC who receive RT, we aimed to identify prognostic markers that could aid in predicting overall survival (OS).
METHODS
METHODS
A retrospective cohort study was conducted at the University of Pennsylvania, involving seventy-eight patients with unresectable BTC treated with definitive intent RT. Comprehensive demographic, clinical, and treatment-related data were extracted from the electronic medical records. Univariate and multivariate Cox regressions were employed to identify predictors of OS after RT. A biomarker model was developed for refined survival prediction.
RESULTS
RESULTS
The cohort primarily comprised patients with good performance status without significant hepatic dysfunction at presentation. The predominant treatment approach involved hypofractionated RT or concurrent 5FU-based chemoRT. Median OS after RT was 12.3 months, and 20 patients (15.6%) experienced local progression with a median time of 30.1 months. Univariate and multivariate analyses identified CA19-9 (above median) and higher albumin-bilirubin (ALBI) grades at presentation as significant predictors of poor OS. Median OS after RT was 24 months for patients with no risk factors and 6.3 months for those with both.
CONCLUSIONS
CONCLUSIONS
Our study demonstrates generally poor but significantly heterogeneous OS in patients with unresectable BTC treated with RT. We have developed a biomarker model based on CA19-9 and ALBI grade at presentation that can distinguish sub-populations with markedly diverse prognoses. This model can aid the clinical management of this challenging disease.
Identifiants
pubmed: 39090660
doi: 10.1186/s13014-024-02481-y
pii: 10.1186/s13014-024-02481-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102Informations de copyright
© 2024. The Author(s).
Références
Bridgewater JA, Goodman KA, Kalyan A, et al. Biliary tract cancer: Epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educational book Am Soc Clin Oncol Annual Meeting. 2016;35:e194–203.
doi: 10.1200/EDBK_160831
Tella SH, Kommalapati A, Borad MJ, et al. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020;21:e29–41.
doi: 10.1016/S1470-2045(19)30733-8
pubmed: 31908303
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.
doi: 10.1056/NEJMoa0908721
pubmed: 20375404
Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (keynote-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England). 2023;401:1853–65.
doi: 10.1016/S0140-6736(23)00727-4
pubmed: 37075781
Oh D-Y, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015.
doi: 10.1056/EVIDoa2200015
pubmed: 38319896
Lamarca A, Palmer DH, Wasan HS, et al. Second-line folfox chemotherapy versus active symptom control for advanced biliary tract cancer (abc-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690–701.
doi: 10.1016/S1470-2045(21)00027-9
pubmed: 33798493
pmcid: 8082275
Foo ML, Gunderson LL, Bender CE, et al. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys. 1997;39:929–35.
doi: 10.1016/S0360-3016(97)00299-X
pubmed: 9369143
Lee KJ, Yi SW, Cha J, et al. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. Cancer Chemother Pharmacol. 2016;78:841–6.
doi: 10.1007/s00280-016-3143-2
pubmed: 27586966
Moureau-Zabotto L, Turrini O, Resbeut M, et al. Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma. BMC Cancer. 2013;13:568.
doi: 10.1186/1471-2407-13-568
pubmed: 24299517
pmcid: 4219485
Crane CH, Macdonald KO, Vauthey JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys. 2002;53:969–74.
doi: 10.1016/S0360-3016(02)02845-6
pubmed: 12095564
Bisello S, Buwenge M, Palloni A, et al. Radiotherapy or chemoradiation in unresectable biliary cancer: a retrospective study. Anticancer Res. 2019;39:3095–100.
doi: 10.21873/anticanres.13445
pubmed: 31177154
Brunner TB, Schwab D, Meyer T, et al. Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis. Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft [et al]. 2004;180:751–7.
doi: 10.1007/s00066-004-1315-1
Ben-David MA, Griffith KA, Abu-Isa E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2006;66:772–9.
doi: 10.1016/j.ijrobp.2006.05.061
pubmed: 17011452
Elganainy D, Holliday EB, Taniguchi CM, et al. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018;7:4880–92.
doi: 10.1002/cam4.1734
pubmed: 30152073
pmcid: 6198206
Chen SC, Chen MH, Li CP, et al. External beam radiation therapy with or without concurrent chemotherapy for patients with unresectable locally advanced hilar cholangiocarcinoma. Hepatogastroenterology. 2015;62:102–7.
pubmed: 25911877
NCI. National cancer institute common terminology criteria for adverse events (CTCAE), Version 4.0. 2010. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . Accessed 17 May 2010.
Dhanasekaran R, Hemming AW, Zendejas I, et al. Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. Oncol Rep. 2013;29:1259–67.
doi: 10.3892/or.2013.2290
pubmed: 23426976
pmcid: 3621732
Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2010;1:274–8.
doi: 10.4103/0974-7788.76794
pubmed: 21455458
pmcid: 3059453
Doussot A, Groot-Koerkamp B, Wiggers JK, et al. Outcomes after resection of intrahepatic cholangiocarcinoma: external validation and comparison of prognostic models. J Am Coll Surg. 2015;221:452–61.
doi: 10.1016/j.jamcollsurg.2015.04.009
pubmed: 26206643
pmcid: 4784264
Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. Nat Reviews Disease Primers. 2021;7:65.
doi: 10.1038/s41572-021-00300-2
pubmed: 34504109
Mosadeghi S, Liu B, Bhuket T, et al. Sex-specific and race/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the USA: an updated analysis of the 2000–2011 surveillance, epidemiology and end results registry. Hepatol Research: Official J Japan Soc Hepatol. 2016;46:669–77.
doi: 10.1111/hepr.12605
Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology (Baltimore MD). 2011;54:173–84.
doi: 10.1002/hep.24351
pubmed: 21488076
Mukkamalla SKR, Naseri HM, Kim BM, et al. Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States. J Natl Compr Cancer Network: JNCCN. 2018;16:370–6.
doi: 10.6004/jnccn.2017.7056
Chan AW, Chong CC, Mo FK, et al. Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis b-associated hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1766–72.
doi: 10.1111/jgh.13339
pubmed: 26992142
Wang YY, Zhong JH, Su ZY, et al. Albumin-bilirubin versus child-pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg. 2016;103:725–34.
doi: 10.1002/bjs.10095
pubmed: 27005482
Zhao S, Wang M, Yang Z, et al. Comparison between child-pugh score and albumin-bilirubin grade in the prognosis of patients with hcc after liver resection using time-dependent Roc. Annals Translational Med. 2020;8:539.
doi: 10.21037/atm.2020.02.85
Su T-S, Yang H-M, Zhou Y, et al. Albumin - bilirubin (albi) versus child-turcotte-pugh (ctp) in prognosis of hcc after stereotactic body radiation therapy. Radiat Oncol. 2019;14:50.
doi: 10.1186/s13014-019-1251-y
pubmed: 30917853
pmcid: 6436219
Toyoda H, Johnson PJ. The albi score: from liver function in patients with hcc to a general measure of liver function. JHEP Reports: Innov Hepatol. 2022;4:100557.
doi: 10.1016/j.jhepr.2022.100557
Kaneko S, Kurosaki M, Tsuchiya K, et al. Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade. Hepatol Research: Official J Japan Soc Hepatol. 2021;51:902–8.
doi: 10.1111/hepr.13673
Tsilimigras DI, Hyer JM, Moris D, et al. Prognostic utility of albumin-bilirubin grade for short- and long-term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: a multi-institutional analysis of 706 patients. J Surg Oncol. 2019;120:206–13.
doi: 10.1002/jso.25486
pubmed: 31025380
Wang Y, Pang Q, Jin H, et al. Albumin-bilirubin grade as a novel predictor of survival in advanced extrahepatic cholangiocarcinoma. Gastroenterol Res Pract. 2018;2018:8902146.
doi: 10.1155/2018/8902146
pubmed: 30622562
pmcid: 6304808
Wang N, Huang A, Kuang B, et al. Progress in radiotherapy for cholangiocarcinoma. Front Oncol. 2022;12:868034.
doi: 10.3389/fonc.2022.868034
pubmed: 35515132
pmcid: 9063097
Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Reviews Clin Oncol. 2018;15:95–111.
doi: 10.1038/nrclinonc.2017.157
Koo T, Park HJ, Kim K. Radiation therapy for extrahepatic bile duct cancer: current evidences and future perspectives. World J Clin Cases. 2019;7:1242–52.
doi: 10.12998/wjcc.v7.i11.1242
pubmed: 31236388
pmcid: 6580339
Network NCC. Biliary tract cancers. Version: 3.2023. In: Editor, editor^editors. Book Biliary tract cancers. Version: 3.2023.; 2023.
Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet (London England). 2014;383:2168–79.
doi: 10.1016/S0140-6736(13)61903-0
pubmed: 24581682